Interesting GILD Put And Call Options For April 25th

Investors in Gilead Sciences, Inc. ( GILD) saw new options become available today, for the April 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GILD options chain for the new April 25th contracts and identified one put and one call contract of particular interest.

The put contract at the $82.00 strike price has a current bid of $3.10. If an investor was to sell-to-open that put contract, they are committing to purchase the stock at $82.00, but will also collect the premium, putting the cost basis of the shares at $78.90 (before broker commissions). To an investor already interested in purchasing shares of GILD, that could represent an attractive alternative to paying $82.50/share today.

Because the $82.00 strike represents an approximate 1% discount to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the put contract would expire worthless. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 55%. Stock Options Channel will track those odds over time to see how they change, publishing a chart of those numbers on our website under the contract detail page for this contract. Should the contract expire worthless, the premium would represent a 3.78% return on the cash commitment, or 27.62% annualized — at Stock Options Channel we call this the YieldBoost.

START SLIDESHOW:
Top YieldBoost Puts of the Nasdaq 100 »

Below is a chart showing the trailing twelve month trading history for Gilead Sciences, Inc., and highlighting in green where the $82.00 strike is located relative to that history:

Loading+chart++2014+TickerTech.com

Turning to the calls side of the option chain, the call contract at the $83.00 strike price has a current bid of $3.25. If an investor was to purchase shares of GILD stock at the current price level of $82.50/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock at $83.00. Considering the call seller will also collect the premium, that would drive a total return (excluding dividends, if any) of 4.55% if the stock gets called away at the April 25th expiration (before broker commissions). Of course, a lot of upside could potentially be left on the table if GILD shares really soar, which is why looking at the trailing twelve month trading history for Gilead Sciences, Inc., as well as studying the business fundamentals becomes important. Below is a chart showing GILD's trailing twelve month trading history, with the $83.00 strike highlighted in red:

Loading+chart++2014+TickerTech.com

Considering the fact that the $83.00 strike represents an approximate 1% premium to the current trading price of the stock (in other words it is out-of-the-money by that percentage), there is also the possibility that the covered call contract would expire worthless, in which case the investor would keep both their shares of stock and the premium collected. The current analytical data (including greeks and implied greeks) suggest the current odds of that happening are 50%. On our website under the contract detail page for this contract, Stock Options Channel will track those odds over time to see how they change and publish a chart of those numbers (the trading history of the option contract will also be charted). Should the covered call contract expire worthless, the premium would represent a 3.94% boost of extra return to the investor, or 28.78% annualized, which we refer to as the YieldBoost.

START SLIDESHOW:
Top YieldBoost Calls of the Nasdaq 100 »

The implied volatility in the put contract example, as well as the call contract example, are both approximately 31%. Meanwhile, we calculate the actual trailing twelve month volatility (considering the last 252 trading day closing values as well as today's price of $82.50) to be 29%. For more put and call options contract ideas worth looking at, visit StockOptionsChannel.com.

If you liked this article you might like

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Stock Market Drop Not Seen Dampening Healthcare Deal Activity

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Centene, LabCorp Among Healthcare Stock Gainers

Centene, LabCorp Among Healthcare Stock Gainers

A Regular Winning Trade Becomes Roadkill in Market Meltdown

A Regular Winning Trade Becomes Roadkill in Market Meltdown

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside